Dr. Raez on the Impact of PD-L1 Status on Immunotherapy Outcomes in NSCLC

EP: 1.Dr. Giaccone on Treatment Options in NSCLC

EP: 2.Dr. Rizvi on Biomarkers of Response to Immunotherapy in NSCLC

EP: 3.Dr. West on the Use of Nivolumab/Ipilimumab in Metastatic NSCLC

EP: 4.Dr. Gandara on the Benefit of Nivolumab/Ipilimumab Plus Chemo in Metastatic NSCLC

EP: 5.Dr. Rizvi on the Implications of the CheckMate-227 Trial With Nivolumab/Ipilimumab in NSCLC

EP: 6.Dr. Wozniak on Optimizing the Use of Immunotherapy in NSCLC

Now Viewing

EP: 7.Dr. Raez on the Impact of PD-L1 Status on Immunotherapy Outcomes in NSCLC

EP: 8.Dr. Garon on Immunotherapy Treatment Considerations in NSCLC

EP: 9.The Evolving Role of Immunotherapy in Metastatic Non–Small Cell Lung Cancer

Luis E. Raez, MD, medical director of Memorial Cancer Institute, and chief of Hematology/Oncology at Memorial Healthcare System, discusses the impact of PD-L1 status on immunotherapy outcomes for patients with non–small cell lung cancer (NSCLC).

Before administering a single-agent immunotherapy, it is important to check a patient's PD-L1 status, as it is currently the only available biomarker for this population, according to Raez. Although several potential biomarkers are under investigation, such as tumor mutational burden, current data are based on PD-L1 expression.

For all patients with lung cancer who do not have any actionable markers or genetic alterations, PD-L1 status is identified, Raez says. If PD-L1 expression is more than 50%, data from the phase 3 KEYNOTE-024 (NCT02142738) and KEYNOTE-042 (NCT02220894) studies indicate that patients will experience a statistically significant benefit from immunotherapy over chemotherapy; this has since become a standard of care in lung cancer, Raez concludes.